Doxycycline in Combination With Sitagliptin on the Glycemic and Cardiac Indices in Patients With Type 2 Diabetes Mellitus
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Change in glycemic profile
研究概览
简要总结
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
盲法说明
open label
入排标准
- 年龄范围
- 40 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female sex more than 40 years old Newly diagnosed type II diabetes. HbA1c more than 6.5
排除标准
- •Patient with chronic kidney disease, hepatic disorders, mental and psychiatric disorders, pregnancy, and lactation
研究组 & 干预措施
control group
patients were on sitagliptin 100mg /day monotherapy
干预措施: Sitagliptin 100mg (Drug)
Comparative group
patients were on sitagliptin 100mg /day monotherapy plus doxycycline 100 mg
干预措施: Sitagliptin 100mg (Drug)
Comparative group
patients were on sitagliptin 100mg /day monotherapy plus doxycycline 100 mg
干预措施: Doxycyclin (Drug)
结局指标
主要结局
Change in glycemic profile
时间窗: 3 months
measurement of glycated hemoglobin
次要结局
未报告次要终点
研究者
Mostafa Bahaa
Teaching assisstant
Tanta University